Analysis of Multifocal Visual Evoked Potentials Using Artificial Intelligence Algorithms.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
03 01 2022
03 01 2022
Historique:
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
27
1
2022
Statut:
ppublish
Résumé
Clinical trials for remyelination in multiple sclerosis (MS) require an imaging biomarker. The multifocal visual evoked potential (mfVEP) is an accurate technique for measuring axonal conduction; however, it produces large datasets requiring lengthy analysis by human experts to detect measurable responses versus noisy traces. This study aimed to develop a machine-learning approach for the identification of true responses versus noisy traces and the detection of latency peaks in measurable signals. We obtained 2240 mfVEP traces from 10 MS patients using the VS-1 mfVEP machine, and they were classified by a skilled expert twice with an interval of 1 week. Of these, 2025 (90%) were classified consistently and used for the study. ResNet-50 and VGG16 models were trained and tested to produce three outputs: no signal, up-sloped signal, or down-sloped signal. Each model ran 1000 iterations with a stochastic gradient descent optimizer with a learning rate of 0.0001. ResNet-50 and VGG16 had false-positive rates of 1.7% and 0.6%, respectively, when the testing dataset was analyzed (n = 612). The false-negative rates were 8.2% and 6.5%, respectively, against the same dataset. The latency measurements in the validation and testing cohorts in the study were similar. Our models efficiently analyze mfVEPs with <2% false positives compared with human false positives of <8%. mfVEP, a safe neurophysiological technique, analyzed using artificial intelligence, can serve as an efficient biomarker in MS clinical trials and signal latency measurement.
Identifiants
pubmed: 35006263
pii: 2778246
doi: 10.1167/tvst.11.1.10
pmc: PMC8762715
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Références
Lancet Neurol. 2012 Feb;11(2):150-6
pubmed: 22236384
Front Neurol. 2018 Aug 03;9:638
pubmed: 30123181
Neuroophthalmology. 2015 Aug 25;39(5):220-233
pubmed: 27928359
CNS Drugs. 2018 Dec;32(12):1159-1171
pubmed: 30267385
J Clin Neurophysiol. 2021 May 1;38(3):186-191
pubmed: 33235179
Doc Ophthalmol. 2008 Jan;116(1):19-27
pubmed: 17680288
Invest Ophthalmol Vis Sci. 1998 May;39(6):937-50
pubmed: 9579473
Invest Ophthalmol Vis Sci. 2011 Aug 29;52(9):6911-8
pubmed: 21791585
PLoS One. 2015 May 28;10(5):e0121084
pubmed: 26020925
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
J Neurol Sci. 2003 Feb 15;206(2):181-5
pubmed: 12559508
Neurology. 2019 Mar 12;92(11):519-533
pubmed: 30787160
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
J Neuropathol Exp Neurol. 1997 Jan;56(1):10-20
pubmed: 8990125
Am J Pathol. 2000 Jul;157(1):267-76
pubmed: 10880396
Lancet Neurol. 2017 Mar;16(3):189-199
pubmed: 28229892
Nat Rev Drug Discov. 2017 Sep;16(9):617-634
pubmed: 28685761
Proc Natl Acad Sci U S A. 2019 Dec 16;:
pubmed: 31843913